MINNEAPOLIS, Dec. 17, 2004 (PRIMEZONE) -- Zimmerman Reed offers Celebrex injury case evaluations, at no cost, at www.zimmreed.com. On Friday, in reaction to the study, Pfizer Inc. (NYSE:PFE) announced an increased risk of cardiovascular events to patients using the popular arthritis and pain relief drug, Celebrex. A long-term cancer-prevention trial, sponsored by the National Cancer Institute, showed that patients taking Celebrex had more than twice the number of major fatal and non-fatal cardiovascular events as those taking a placebo. This study comes only a few months after Vioxx was pulled from the market, due to similar concerns.
Celebrex(r), also known as Celecoxib(r), is used to relieve pain, tenderness, inflammation and stiffness caused by arthritis by targeting COX-2 inhibitors. These enzymes play a key role in pain and inflammation. The FDA approved Celebrex in 1999 for joint manufacture by Searle Pharmaceuticals and Pfizer Pharmaceuticals. According to the manufacturers, Celebrex has been prescribed millions of times since its approval and is currently the most frequently prescribed arthritis drug.
For a free comprehensive Celebrex Case Evaluation, go to www.zimmreed.com. For further information, contact Ron Goldser at 800.755.0098.